The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation

首页> 外文期刊>Journal of pediatric urology >The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation

【24h】

The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation

机译：Mirabegron在儿童和青少年中的药代动力学，安全性和耐受性，具有神经源性排尿管过度或特发性过度活性膀胱和基于人口药代动力学模型的儿科剂量估算的发展

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction

机译：介绍

著录项

来源
《Journal of pediatric urology》 |2020年第1期|共10页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类儿科学;
关键词
Mirabegron; Neurogenic detrusor overactivity; Overactive bladder; Pediatrics; Pharmacokinetics;

机译：m拉萨比克;神经源性排尿管过度效应;过度活跃的膀胱;儿科;药代动力学;

相似文献

外文文献
中文文献
专利

1. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation [J] . Journal of pediatric urology . 2020,第1期

机译：Mirabegron在儿童和青少年中的药代动力学，安全性和耐受性，具有神经源性排尿管过度或特发性过度活性膀胱和基于人口药代动力学模型的儿科剂量估算的发展
2. A MULTICENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF SOLIFENACIN SUCCINATE SUSPENSION IN PEDIATRIC SUBJECTS FROM 5 TO LESS THAN 18 YEARS OF AGE WITH NEUROGENIC DETRUSOR OVERACTIVITY (NDO). [J] . Bosman B., Tannenbaum S., Winklewski P., Neurourology and urodynamics. . 2013,第6期

机译：多中心，开放式，单剂量研究评估小儿科受试者中5到18岁以下神经原性胶体活动过度的药动学，安全性和耐受性甜菜碱糖苷悬浮液的耐受性。
3. Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity [J] . Stacey Tannenbaum, Martin den Adel, Walter Krauwinkel, Pharmacology Research & Perspectives . 2020,第6期

机译：索尔替芬素的药代动力学在具有过热膀胱或神经源性排尿管过度的儿科群体中的药代动力学
4. Electrical Stimulation of the Transcutaneous Posterior Tibial Nerve for the Treatment of Patients with Detrusor Overactivity Due to Neurogenic Hiperactive Bladder in Multiple Sclerosis A Case Study [C] . Fabiana S. B. Perez, Luciana R. Tenorio Peixoto, Fabiano Soares, International Conference on Biomedical Electronics and Devices . 2014

机译：经皮后胫骨神经的电气刺激治疗多发性硬化中神经源性膀胱患者患者的患者案例研究
5. Pharmacokinetic modeling of vancomycin in children, pre-adolescent, and adolescent patients: Development, assessment, and application [D] . Asiri, Yousif Abdu 1998

机译：万古霉素在儿童，青少年前和青少年患者中的药代动力学模型：开发，评估和应用
6. Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity [O] . Stacey Tannenbaum, Martin den Adel, Walter Krauwinkel, 2020

机译：索尔替芬素的药代动力学在具有过热膀胱或神经源性排尿管过度的儿科群体中的药代动力学
7. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model–based pediatric dose estimation [O] . Søren Rittig, Małgorzata Baka-Ostrowska, Camilla Tøndel, 2020

机译：Mirabegron在儿童和青少年中的药代动力学，安全性和耐受性，具有神经源性排尿管过度或特发性过度活性膀胱和基于人口药代动力学模型的儿科剂量估算的发展

The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation

摘要

著录项

相似文献

相关主题

期刊订阅